daclizumab

Type: Product
Name: daclizumab
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Hangout with us at ECTRIMS

Following on from the success of our previous public engagement activity MS Question Time , at the joint ACTRIMS-ECTRIMS conference this year in Boston we are holding three ‘Question Time Hangouts’. The ACTRIMS-ECTRIMS meeting is an important date ... [Published Multiple Sclerosis Research - Aug 24 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Politics: drug pricing

Do Pharma CEOs' deserve their large bonuses? #MSBlog #MSResearch "Do MS DMTs justify their current premium? A large number of MS drugs are repurposed and hence their risk of failure has been low. Despite this the costs remain high.""Re-purposed licensed ... [Published Multiple Sclerosis Research - Aug 24 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 2 reports

Biogen Strengthens MS Portfolio with Plegridy FDA...

Meanwhile, data on Plegridy showed that it significantly reduced annualized relapse rate at one year by 36% compared to placebo. The risk of 12-week confirmed disability progression was down by 38% in patients on Plegridy compared to placebo. Plegridy ... [Published Nasdaq - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

NK cells are they important in MS

Galuppo M, Giacoppo S, Sessa E, Bramanti P, Mazzon E. Are natural killer cells involved in multiple sclerosis aetiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.  J Neurol Sci. 2014. pii: S0022-510X(14)00491-2. doi: 10.1016/j.jns.2014.07.045. ... [Published Multiple Sclerosis Research - Aug 18 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

MSology at ACTRIMS-ECTRIMS – BOSTON 2014

The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ... [Published MSology - Aug 14 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 2 reports

MS market to reach $20 billion in 2023 boosted by five new therapies

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will help drive total sales across the MS market in the USA, France, Germany, Italy, Spain, UK and Japan to more than $20 billion in 2023, reflecting 4% annual ... [Published Pharma Letter - Aug 08 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line

Daclizumab High Yield Process (DAC HYP) is intended to be used for the long-term first or second line treatment of relapsing forms of multiple sclerosis . If licensed, DAC HYP will offer an additional treatment option for this patient group. DAC HYP is ... [Published BioPortfolio - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023

BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, ... [Published PR Newswire: General Business - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

New results for two novel therapies

Promising new results have now been published for two monoclonal antibody (MAb) drugs in development that may provide additional options over the next few years. MAbs are biological agents that target highly specific targets. MAbs currently used in MS ... [Published MSology - Aug 07 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Can Biogen Idec Take Wing With Tecfidera?

By William Meyers :Biogen Idec (NASDAQ: BIIB ) generates most of its revenue from drugs for MS ( multiple sclerosis ), but also receives substantial sums from other disease indications. It recently has gained approval for its hemophilia therapies. Biogen ... [Published BioPortfolio - Jul 29 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 3 reports

Biogen Idec's (BIIB) CEO George Scangos on Q2 2014 Results - Earnings Call Transcript

OperatorGood morning. My name is Tiffany and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Idec Q2 2014 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. ... [Published Seeking Alpha - Jul 23 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 4 reports

Another eagle has landed: phase 3 daclizumab trial is positive

Daclizumab: another repurposed drug resurfaces as a treatment for MS #MSBlog #MSResearch Press Release Biogen-Idec and Abbvie have announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority ... [Published Multiple Sclerosis Research - Jun 16 2014]

Quotes

"Regarding this issue I am not sure of what is the correct answer, except to say that Pharma will charge as much as the market will support. This means we need systems in place to keep the prices reasonable, which is what EU organisations such as NICE do. However,  this does not occur in the US and hence the costs of drugs in the US is much higher than outside of the US. This means that the US is subsiding drug prices, and drug development, for the rest of the world. The latter cannot go on indefinitely. What is a problem is when the new drugs are truly transformational and without them people with certain disease will die. This issue has recently been raised with the pricing of the new hepatitis C drugs and I have addressed this on the blog quite recently. Similarly, should Pharma bosses get paid so much? For example John Martin, the CEO of Gilead who make the new hepatitis C drug, received $90 million in 2012. Economists would argue that if you believe in the power of the market to deliver then you should let it work its magic; if you try and prevent the market working it won't deliver on what is needed. I am not sure if buying and prescribing of drugs is a real market; sick people don't have a choice when it comes to certain treatments. What do you think? Is the prescription drug market a real market?"
"As this segment of the MS market shrinks, we expect to get an increasing share of this segment as a result of the patient convenience," he said. "Plegridy represents the most significant innovation in the interferon class in over a decade."
Original Article: NEXT ARTICLE More From BioPortfolio on "Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line"
If all goes according to plan Biogen Idec will eventually have "six important medicines to offer MS patients with different needs" said chief executive George Scangos last week, who said that - despite the availability of oral therapies for MS - interferons will continue to play...

More Content

All (49) | News (24) | Reports (0) | Blogs (25) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 26 2014]
Hangout with us at ECTRIMS [Published Multiple Sclerosis Research - Aug 24 2014]
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 21 2014]
Biogen Strengthens MS Portfolio with Plegridy F... [Published Nasdaq - Aug 19 2014]
Biogen Strengthens MS Portfolio with Plegridy F... [Published Zacks.com - Aug 19 2014]
FDA approves Biogen Idec's long-acting MS therapy [Published PMLive - Aug 18 2014]
NK cells are they important in MS [Published Multiple Sclerosis Research - Aug 18 2014]
Market Update: Biogen Idec Inc (NASDAQ:BIIB) – ... [Published Jutia Group - Aug 16 2014]
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
MS market to reach $20 billion in 2023 boosted ... [Published Pharma Letter - Aug 08 2014]
MS market set to grow 4% annually [Published PMLive - Aug 08 2014]
Daclizumab High Yield Process for relapsing for... [Published BioPortfolio - Aug 08 2014]
The Launch of Five Immunomodulatory Therapies f... [Published PR Newswire: General Business - Aug 07 2014]
New results for two novel therapies [Published MSology - Aug 07 2014]
Is AbbVie A Long-Term Buy? [Published Seeking Alpha - Aug 05 2014]
A randomized controlled trial of daclizumab ver... [Published 7thSpace - Jul 30 2014]
Can Biogen Idec Take Wing With Tecfidera? [Published BioPortfolio - Jul 29 2014]
Can Biogen Idec Take Wing With Tecfidera? [Published Seeking Alpha - Jul 29 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jul 28 2014]
Plegridy approval underlines Biogen Idec's domi... [Published PMLive - Jul 28 2014]
Humira Still Key to AbbVie [Published Motley Fool Discussion Boards - Jul 25 2014]
AbbVie's (ABBV) CEO Richard Gonzalez on Q2 2014... [Published Seeking Alpha - Jul 25 2014]
AbbVie Reports Second-Quarter 2014 Financial Re... [Published Scottrade - Jul 25 2014]
Biogen Idec's (BIIB) CEO George Scangos on Q2 2... [Published Seeking Alpha - Jul 23 2014]
Biogen Idec Beats And Raises: Reassessing Its P... [Published Seeking Alpha - Jul 23 2014]
Biogen Idec Beats Estimates, Raises Guidance [Published Bidness Etc - Jul 23 2014]
Biogen Idec Second Quarter 2014 Revenues Increa... [Published Tamar Securities - Jul 23 2014]
Daclizumab phase 3 trial results announced [Published MS News - Jun 30 2014]
Treg function depleted by Daclizumab but functi... [Published Multiple Sclerosis Research - Jun 19 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Hangout with us at ECTRIMS [Published Multiple Sclerosis Research - Aug 24 2014]
Following on from the success of our previous public engagement activity MS Question Time , at the joint ACTRIMS-ECTRIMS conference this year in Boston we are holding three ‘Question Time Hangouts’. The ACTRIMS-ECTRIMS meeting is an important date ...
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
Do Pharma CEOs' deserve their large bonuses? #MSBlog #MSResearch "Do MS DMTs justify their current premium? A large number of MS drugs are repurposed and hence their risk of failure has been low. Despite this the costs remain high.""Re-purposed licensed ...
NK cells are they important in MS [Published Multiple Sclerosis Research - Aug 18 2014]
Galuppo M, Giacoppo S, Sessa E, Bramanti P, Mazzon E. Are natural killer cells involved in multiple sclerosis aetiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.  J Neurol Sci. 2014. pii: S0022-510X(14)00491-2. doi: 10.1016/j.jns.2014.07.045. ...
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ...
The Launch of Five Immunomodulatory Therapies f... [Published PR Newswire: General Business - Aug 07 2014]
BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, ...
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.